Reuters logo
BRIEF-Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix
October 27, 2017 / 11:38 AM / a month ago

BRIEF-Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix

Oct 27 (Reuters) - Abbvie Inc

* Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain

* Abbvie inc - ‍expects PDUFA date for FDA to complete its review will be in Q2 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below